Approved comparison material connected to this topic.
4 total recordsSource comparisons are presented without a generated winner.
Cerebrolysin BDNF/NGF mimetic. Activates TrkB receptors, reduces excitotoxicity and apoptosis 0–72 hours post-stroke (acute neuroprotection) Strong. Multiple Phase III RCTs with NIHSS improvement data Acute is…
BPC-157 VEGF upregulation and eNOS stabilization; promotes angiogenesis and axonal regrowth 0–72 hours post-stroke; sustained for 14–28 days Subcutaneous injection at 200–500 mcg daily Reduced MCAO infarct vol…
Cerebrolysin NGF/BDNF upregulation, neurotrophic support 30–50ml IV daily for 21 days Subacute (7 days–6 months) Phase III RCTs (Cochrane review) Strongest clinical evidence for motor and ADL improvement. Gold…
BPC-157 Angiogenesis, eNOS stabilization, VEGF upregulation 0–72 hours (acute phase) Subcutaneous 42% infarct volume reduction in rodent MCAO models (2021) Strongest preclinical evidence for acute neuroprotect…